pre-emptively before the second birthday, 3, 4 minimizes or prevents spontaneous bleeding events and arthropathy. 5, 6 The role of FVIII prophylaxis in MHA is less clear, given that these patients already have a baseline FVIII level of ≥0.01 IU/mL and a variable bleeding phenotype. However, a subgroup of these patients suffer frequent haemarthroses and are therefore managed with FVIII prophylaxis. 7 Although FVIII prophylaxis effectively reduces the frequency of bleeding events, individualization of treatment is required to achieve the best bleed control. 8, 9 Although it is often advised to maintain a trough FVIII level ≥0.01 IU/mL, complete bleed-avoidance commonly requires a higher level. 10, 11 Prophylaxis is also demanding, prone to poor compliance and, as currently practiced, does not completely prevent arthropathy. 12, 13 Consequently, many patients are still treated with sub-optimal prophylaxis or on-demand treatment, resulting in a continuing unmet need.
Bypass therapy administered on-demand or as prophylaxis in patients with persistent inhibitors is only partially effective in treating or preventing haemarthroses. [14] [15] [16] Consequently, these patients experience a higher annualized bleed rate and reduced life expectancy than patients lacking inhibitors. 17 The extent to which this morbidity may be minimized or prevented by early inhibitor eradication through immune tolerance induction is unknown.
Treatment and disease outcome of HA by age, disease severity and inhibitor status in complete national haemophilic cohorts are not well documented. The THUNDER study (Treatment of Haemophilia, Unmet Need and Disease Epidemiology in the Real world) was established to provide an analysis of real-world treatment of HA in the UK, derived prospectively from data collected by the UK National Haemophilia Database (NHD) and the Haemtrack (HT) patient-reported treatment diary. 18 Treatment practice and patterns were analysed in relation to patient-reported and objectively measured outcomes in the UK cohort of patients with SHA or MHA treated during 2015, to evaluate continued unmet need in this patient-group.
| MATERIAL S AND ME THODS

| Study objectives
The objective of this study was to describe the current standard of care and to evaluate unmet need in UK patients with SHA and MHA, by age and inhibitor status in the whole UK HT population.
We evaluated the treatment regimen and outcome as reflected by patient-reported annualized bleed/joint-bleed rates (ABR/ABJR);
bleed-related pain and interruption of daily function, in patients fulfilling pre-set HT-compliance criteria only. Haemophilia joint health score (HJHS) was analysed where available.
| Data source and patient population
The UK NHD prospectively collects data for all UK patients registered as having a bleeding disorder. Diagnoses, adverse events and mortality are updated electronically in real time and treatment data are reported quarterly, including individual patient product and volume.
The HT system is a primarily electronic, home-therapy patientreporting diary, which integrates with NHD systems. 18 
| Haemtrack reported treatment practices and bleeding outcomes in SHA and MHA
During the study period, there were a total of 1620 bleeds reported amongst the 770 individuals meeting the HT-compliance criteria; 52.8% of these were reported to be traumatic. The cause of bleeding events varied with age; 63.0% of bleeds in individuals aged 0-11 years were reported as traumatic, compared with 48.2% in patients ≥40 years.
| Non-inhibitor patients
Of 717 non-inhibitor patients with SHA or MHA reporting HT-compliant data during the study period, 563 (78.5%) had SHA, and 154 (21.5%) MHA. Of these, 465 (82.5%) with SHA and 106 (68.8%) with MHA reported using regular prophylaxis. The proportion of patients using prophylaxis was highest in younger patients and fell progressively with increasing age. The distribution by age, treatment regimen, ABR and AJBR of the group with SHA reporting prophylaxis is summarized in Table 2 and Figure spectively. In the SHA group using prophylaxis, 29% were bleed-free;
38% were joint-bleed-free. In the on-demand group, 19% were bleedfree and 28% reported no joint bleeding. ABR and AJBR increased with age in both the prophylaxis and on-demand groups ( Table 2 ,
Figures 2 and 3).
TA B L E 1 Study population categorized according to age at study mid-point and compliance with Haemtrack (HT) reporting for (a) severe haemophilia A, and (b) moderate haemophilia A 
F I G U R E 1 Distribution of study population
The ABR in the subgroup of MHA patients who met the HT-compliance criteria was higher than SHA: median (IQR) ABR/AJBR was with MHA reporting prophylaxis, 24% and 30% were bleed-free or joint-bleed-free, respectively. In the on-demand group, this was 10%
and 15%, respectively. TA B L E 2 Number of non-inhibitor Haemtrack-compliant patients with SHA, categorized according to age, treatment type and associated annual bleed rate (ABR)/annual joint-bleed rate (AJBR) with MHA who had a HJHS performed suggests a similar pattern to SHA, although patient numbers were too low to confirm this definitively ( Figure 5 ).
| Inhibitor patients
| Pain associated with bleeding events
Pain associated with bleeding events is reported to HT on a scale of one to six, six being the highest level of pain. Patients are also requested to define bleeding episodes as minor or major/life-threatening. The median pain score reported for all minor bleeds (n = 1181) was 3.0. For major bleeding (n = 458), the median pain score was 5.0, although the number of episodes was substantially less than the number of minor bleeding events. There was no difference in reported pain according to the nature of the bleed (spontaneous, surgery/dental or trauma/activity).
| Disruption to planned activities associated with bleeding events and time from bleed-onset to treatment
During the study period, 51.0% of bleeding episodes were reported to disrupt a planned activity. There appeared to be no relationship between the frequency of disruption and the age of the patient. The median (IQR) time elapsed from bleed-onset to treatment was 2.0 (1.0-4.0) hours.
| D ISCUSS I ON
We report a prospective study of treatment practices and associated outcomes in a national cohort of 2674 UK patients with SHA and MHA during 2015. Around 53% of this population used HT, 55% of whom fulfilled compliance criteria, permitting analysis of treatment regimen and outcome. The SHA HT cohort are a representative sample of UK patients with SHA lacking inhibitors, 18 but HT-using patients with MHA have a predominantly severe bleeding phenotype.
The proportion of children using prophylaxis was high (94%), decreasing to 74% of older adults. Prophylaxis has been the standard of care in children for many years. 6, 19 The gradual uptake of prophylaxis in adult patients has been less consistent, despite good evidence to support its use. 20 There is considerable national variation, from zero to 100%, in the use of prophylaxis amongst adult patients, even in countries with similar health care systems and wealth. 21, 22 The proportion of adults using prophylaxis in the UK has increased substantially over the past 10 years. Although we found relatively low ABRs in patients treated on-demand, this probably reflects treatment F I G U R E 4 Median haemophilia joint health score for patients with severe haemophilia A and moderate haemophilia A, categorized according to treatment type and age. The line represents the median value; the box interquartile range and the whiskers the lowest data still within 1.5 IQR of the lower quartile, and the highest data still within 1.5 IQR of the upper quartile selection bias, since on-demand regimens are generally used in patients with a relatively mild bleeding phenotype in countries where
prophylaxis is the standard of care.
The median ABR and AJBR was low in non-inhibitor patients
with SHA treated prophylactically, especially in children <12 years.
However, large interpersonal variation was observed, and a significant proportion of adult patients with SHA still have an unacceptably high ABR. This may relate to established arthropathy and the difficulty older patients experience distinguishing early bleeding from arthropathic discomfort or to inadequate prophylaxis.
We show that prophylaxis is only partially effective in preventing self-reported bleeding; only 29% of patients with SHA and 24% of patients with MHA using prophylaxis reported that they were bleedfree. This suggests that individual tailoring of prophylaxis could be improved. Current UK guidelines recommend maintaining a trough FVIII level of>0.01 IU/mL. 3 However, patients with MHA and a me- Although determining inhibitor epidemiology was not a primary objective of this analysis, our data allow us to calculate an overall inhibitor prevalence of 7.2%, consistent with previous estimations in unselected HA populations. [23] [24] [25] It is interesting to note that in the HT subgroup the prevalence of inhibitors is remarkably similar (6.9%).
Patients with persistent inhibitors to FVIII have significantly higher ABR and HJHS than non-inhibitor patients with a similar factor VIII level, especially amongst the older patients, where pre-existing arthropathy probably increases an individual's propensity to bleed. Surprisingly, although one might expect some arthropathy to develop in the period before successful inhibitor eradication, we found patients with a past inhibitor history to have a similar HJHS to patients who had never had an inhibitor. This reinforces the importance of prompt, active inhibitor eradication. Although this is the largest reported data set of HJHS, only a small number of older patients are reported and there is likely to be a degree of inter-and intra-centre joint-scoring variability. 31 Furthermore, we are unable to confirm the presence of co-morbid musculoskeletal conditions that may contribute to HJHS. Although we have drawn only broad and general conclusions from our HJHS data, as the electronic reporting of HJHS to the NHD becomes more routine and the data set expands, we will be able link HJHS to treatment frequency and intensity in addition to disease severity and other co-morbid conditions. This is the first large-scale study using data derived from the HT system, demonstrating the great potential for this tool to generate treatment-level data in large cohorts of patients. Uptake and compliance with the system continue to increase. The data set will evolve, and there is potential to link with other large national databases and information systems, expanding the number of non-traditional outcome measures available for analysis.
The THUNDER study demonstrates the limitations of prophylaxis as recently practiced in the UK. Whilst outcomes in children appear excellent, prophylaxis has not succeeded in attaining the desired bleed-free status in many children and most adults. Arthropathy is observed from early adulthood onwards. Haemarthroses, when they occur, have a significant impact on daily life. Strategies to improve these outcomes should be targeted to reduce bleeding in patients with high ABRs. This should include more intense individualization of prophylaxis, potentially requiring trough FVIII levels beyond 0.01-0.02 IU/mL, optimized pharmacokinetically in some patients.
Prophylaxis should be started early in patients with MHA if spontaneous bleeding episodes occur. We should aim for our patients to be bleed-free and, as newer agents become increasingly available for routine clinical use, this may soon become a realistic aspiration.
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